CN111773203A - 一种包含盐酸去氧肾上腺素组合物的制备工艺 - Google Patents
一种包含盐酸去氧肾上腺素组合物的制备工艺 Download PDFInfo
- Publication number
- CN111773203A CN111773203A CN202010417513.8A CN202010417513A CN111773203A CN 111773203 A CN111773203 A CN 111773203A CN 202010417513 A CN202010417513 A CN 202010417513A CN 111773203 A CN111773203 A CN 111773203A
- Authority
- CN
- China
- Prior art keywords
- stirring
- phenylephrine hydrochloride
- preparation
- amount
- acetaminophen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003733 phenylephrine hydrochloride Drugs 0.000 title claims abstract description 48
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 65
- 229960005489 paracetamol Drugs 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 32
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 29
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 27
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims abstract description 24
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 206010011224 Cough Diseases 0.000 claims abstract description 5
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 5
- 206010039101 Rhinorrhoea Diseases 0.000 claims abstract description 5
- 208000036071 Rhinorrhea Diseases 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 63
- 239000000463 material Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 239000008213 purified water Substances 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 239000006184 cosolvent Substances 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 239000000230 xanthan gum Substances 0.000 claims description 14
- 235000010493 xanthan gum Nutrition 0.000 claims description 14
- 229940082509 xanthan gum Drugs 0.000 claims description 14
- 229920001285 xanthan gum Polymers 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 13
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 12
- 235000010234 sodium benzoate Nutrition 0.000 claims description 12
- 239000004299 sodium benzoate Substances 0.000 claims description 12
- 239000000375 suspending agent Substances 0.000 claims description 11
- 239000004376 Sucralose Substances 0.000 claims description 10
- 239000000049 pigment Substances 0.000 claims description 10
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 10
- 235000019408 sucralose Nutrition 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 9
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- 241000219095 Vitis Species 0.000 claims description 8
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 8
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 8
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 8
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 235000013599 spices Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 235000012741 allura red AC Nutrition 0.000 claims description 5
- 239000004191 allura red AC Substances 0.000 claims description 5
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 claims description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 5
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000004283 Sodium sorbate Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 claims description 2
- 235000019250 sodium sorbate Nutrition 0.000 claims description 2
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 1
- 239000007968 orange flavor Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 abstract description 27
- 238000004090 dissolution Methods 0.000 abstract description 24
- 239000002253 acid Substances 0.000 abstract description 6
- 150000007513 acids Chemical class 0.000 abstract description 6
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 5
- 150000001299 aldehydes Chemical class 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 3
- 150000002739 metals Chemical class 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 239000013558 reference substance Substances 0.000 description 11
- 238000001514 detection method Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 238000010008 shearing Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000005070 sampling Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 229960004365 benzoic acid Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007971 pharmaceutical suspension Substances 0.000 description 3
- 229960001802 phenylephrine Drugs 0.000 description 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 3
- 229960003885 sodium benzoate Drugs 0.000 description 3
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明包含盐酸去氧肾上腺素组合物的制备工艺,所述组合物的活性成分包括盐酸去氧肾上腺素、马来酸氯苯那敏、对乙酰氨基酚和氢溴酸右美沙芬。本发明因盐酸去氧肾上腺素可在氧、醛、某些酸和金属存在下降解,采用本发明制备,在含有枸橼酸或其他酸类的情况下,其盐酸去氧肾上腺素在PH值4.5‑5.0条件下稳定,优选PH值4.7‑5.0。另外,采用本发明方法制备的混悬液,具有制备方法简单,稳定性好,药物的溶出度高,疗效好优点。本发明对发热咽痛、鼻塞咳嗽、流鼻涕等有特效。但是4岁以下人群不可用,4‑6岁遵医嘱。
Description
技术领域
本发明属药物研发技术领域,具体涉及一种包含盐酸去氧肾上腺素组合物的制备工艺,更具体的讲,所述制备工艺为混悬剂的制备工艺。
背景技术
呼吸道疾病包括多种疾病,多由病毒或病菌引起,如感冒和流感以及过敏鼻炎等,其表现的症状主要为发热、鼻塞、流涕、咳嗽、打喷嚏或头痛,如不及时治疗,可引起诸多并发症,给人们身体带来严重危害。
盐酸去氧肾上腺素为α肾上腺素受体激动药,常和抗组织胺药、镇咳药、祛痰药、退热药、抗炎药和治疗呼吸道疾病如感冒和流感等其他药物合用,主要起到粘膜收缩作用,以增加祛痰和治疗鼻塞、鼻炎等功效。
现有含盐酸去氧肾上腺素单方或复方制剂有很多,如针剂、片剂、胶囊剂、滴眼剂等。同领域技术人员可知的,当制备成适宜的产品时,必须要考虑的首要问题是药物的稳定性和药物的释放速度。因此,对剂型的选择和工艺参数的设定,是一项挑战性的工作,具体的讲,如在制备口服液时,因组方不合理或在制备时未考虑其制备的工艺条件,会使药液变色或活性成分降解,有降低疗效和产生副作用的风险。
专利号为“2007800304895”,专利名称为“含有苯肾上腺素的药用混悬剂及其制备方法”的发明专利,公开了一种药物混悬剂及其相关方法,其实施例1至实施例4为其优选的制备方法,其方法大概为:(1)向具有高剪切功能的混合机内加入一定量的水;(2)再加入微晶纤维素、羧甲基纤维素,在880R/S下剪切约20分钟;(3)加入甘油和氢溴酸右美沙芬,在880R/S下剪切混合约20分钟至溶解;(4)加入黄原胶,在880R/S下剪切混合约20分钟直至水化;(5)加入山梨醇纳和蔗糖,在450R/S下剪切混合30分钟;(6)加入柠檬酸、苯甲酸钠,加入马来酸氯苯那敏和盐酸苯肾上腺素,在880R/S下剪切混合30分钟;(7)加入对乙酰氨基酚(细粉级)、染料和调味剂,在880R/S下剪切混合20分钟;(8)加纯化水至最终体积,在真空度为4.0psia(磅/平方英寸绝对值)真空脱气,即得(所有混合步骤都在真空下进行)。
本发明人发现,按其方法制备的混悬液,粘稠度大,并且剪切混合时间越长,粘稠度越大,经5次不同时间取样检测溶出度(以盐酸去氧肾上腺素、马来酸氯苯那敏、氢溴酸右美沙芬和对乙酰氨基酚进行含量为检测指标),其溶出度低于60%,由此说明,溶出度低,生物利用度就低,相应的疗效也低。
发明内容
发明内容简述如下:
本发明包含盐酸去氧肾上腺素组合物的制备工艺,所述组合物的活性成分包括盐酸去氧肾上腺素、马来酸氯苯那敏、对乙酰氨基酚和氢溴酸右美沙芬,制备成混悬剂还含有一定的增稠剂、助溶剂、PH调节剂、助悬剂、防腐剂、矫味剂等。本发明因盐酸去氧肾上腺素可在氧、醛、某些酸和金属存在下降解,经研究发现,采用本发明方法制备的混悬液,在含有枸橼酸或其他酸类的情况下,其盐酸去氧肾上腺素在PH值4.5-5.0条件下稳定,优选PH值4.7-5.0。具体方法大致为,先将助悬剂进行剪切混合,然后在不包含氢溴酸右美沙芬成分时,将剪切混合均匀的助悬剂与马来酸氯苯那敏、盐酸去氧肾上腺素、对乙酰氨基酚等溶解/或熔融液及其辅料进行剪切混合,最后加入氢溴酸右美沙芬进行混合,用溶剂调至配制量,加入 PH调节剂调节PH值即得。采用本方法制备的混悬液,具有制备方法简单,药液稳定,溶出度高,生物利用度高优点。
需要指明的是,本发明所述组合物可以制成混悬液外,还可以制成其他如合剂、糖浆剂、等口服液体制剂和制成填充液体的胶囊、填充液体的糖块等。
本发明对发热咽痛、鼻塞咳嗽、流鼻涕等有特效。但是4岁以下人群不可用,4-6岁遵医嘱。
发明内容详述如下:
除非另外指明,本文所有重量或体积均是在18-25℃条件下,对组合物中的活性药物成分和制备成混悬液所需的辅料进行称量的。
为实现本发明,本发明的技术方案如下:
处方:1000ml中含:
药物活性成分:盐酸去氧肾上腺素0.5g、马来酸氯苯那敏0.2g、对乙酰氨基酚0.032g、氢溴酸右美沙芬1.00g。
辅料:助溶剂1 50-150g、助溶剂2 600-800g、增稠剂0.8-2.0g、助悬剂1.00-10.00g、防腐剂0.8-1.5g、矫味剂1.00-5.00g、PH调节剂适量、色素10-40mg、香料1-3ml、溶剂适量
制法:
原辅料的处理:对乙酰氨基酚:粉碎,过80-120目筛;色素、香料:先分别用溶剂配制成一定浓溶液,备用;
A、取处方量的马来酸氯苯那敏、盐酸去氧肾上腺素、对乙酰氨基酚和防腐剂置洁净的容器中,加入55-65℃的溶剂适量,搅拌至熔融/或溶解状态,加入助溶剂2,继续搅拌20-60min,静止,过滤,得物料1;
B、取处方量的助悬剂置均质机中,加入适量溶剂,用均质机(10000-20000r/s)均质搅拌 20-50s,得物料2;
C、将上述物料1转移至物料2中,用均质机(10000-20000r/s)继续均质搅拌20-50s,得物料3;
D、取助溶剂1置洁净的容器中,加入增稠剂,搅拌至熔融/或溶解,加入处方量的氢溴酸右美沙芬,搅拌均匀,55-65℃条件下搅拌30-60分钟,得物料4;
E、将物料3转移至物料4中,加入处方量的矫味剂,色素溶液,香料溶液,加入溶剂至配制量,搅拌100-150分钟,用PH调节剂调节PH值为4.5-5.0,继续搅拌至均质状态,过滤,即得本发明。
所述助溶剂1为甘油,助溶剂2为山梨醇。
所述增稠剂包括但不限于黄原胶、卡波姆、交联聚丙烯酸钠、泊洛沙姆、聚乙烯醇、海藻酸钠,进一步优选地黄原胶。
所述助悬剂包括但不限于微晶纤维素,聚乙烯吡咯烷酮水溶液或羟丙基甲基纤维素一种或几种,进一步优选微晶纤维素。
所述防腐剂包括但不限于苯甲酸、苯甲酸钠、山梨酸、山梨酸钠,进一步优选苯甲酸钠。
所述矫味剂包括但不限于蔗糖、甜菊素、三氯蔗糖,进一步优选三氯蔗糖。
所述PH调节剂包括但不限于磷酸氢钠、无水枸橼酸、磷酸二氢钾或磷酸二氢钠,进一步优选无水枸橼酸。
所述色素包括但不限于柠檬黄、橘黄、亮蓝、诱惑红,优选亮蓝和诱惑红。
所述香料包括但不限于葡萄香精、苹果香精、桔子香精,优选葡萄香精。
所述溶剂包括但不限于水、丙二醇、乙醇、聚乙二醇或他们的混合物,所述水为纯化水、去离子水或蒸馏水,本发明优选纯化水。
本发明优选的处方和制法如下:
处方:1000ml中含:
药物活性成分:盐酸去氧肾上腺素0.5g、马来酸氯苯那敏0.2g、对乙酰氨基酚0.032g、氢溴酸右美沙芬1.00g。
辅料:甘油100.00g、山梨醇670.00g、黄原胶1.12g、微晶纤维素0.0075g、苯甲酸钠1.2g、三氯蔗糖2.4g、无水枸橼酸适量、纯化水适量。
制法:
原辅料的处理:(1)对乙酰氨基酚,粉碎,过80-120目筛;(2)色素、香料先用水配制成一定浓溶液。
A、取处方量的马来酸氯苯那敏、盐酸去氧肾上腺素、对乙酰氨基酚和苯甲酸钠置洁净的容器中,加入55-65℃的纯化水适量,搅拌至熔融/或溶解状态,加入山梨醇,继续搅拌20-60min,静止,过滤,得物料1;
B、取处方量的微晶纤维素置均质机中,加入适量纯化水,用均质机(10000-20000r/s)均质搅拌20-50s,得物料2;
C、将上述物料1转移至物料2中,用均质机(10000-20000r/s)继续均质搅拌20-50s,得物料3;
D、取甘油置洁净的容器中,加入黄原胶,搅拌至熔融/或溶解,加入处方量的氢溴酸右美沙芬,搅拌均匀,55-65℃条件下搅拌30-60分钟,得物料4;
E、将物料3转移至物料4中,加入处方量的三氯蔗糖、亮蓝、诱惑红,葡萄香精,加入纯化水至配制量,搅拌100-150分钟,用无水枸橼酸调节PH值为4.7-5.0,继续搅拌至均质状态,过滤,即得本发明。
有益效果
本发明包含盐酸去氧肾上腺素组合物的制备工艺,所述组合物的活性成分包括盐酸去氧肾上腺素、马来酸氯苯那敏、对乙酰氨基酚和氢溴酸右美沙芬。本发明因盐酸去氧肾上腺素可在氧、醛、某些酸和金属存在下降解,采用本发明制备,在含有枸橼酸或其他酸类的情况下,其盐酸去氧肾上腺素在PH值4.5-5.0条件下稳定,优选PH值4.7-5.0。另外,采用本发明方法制备的混悬液,具有制备方法简单,稳定性好,药物的溶出度高,疗效好优点。
本发明对发热咽痛、鼻塞咳嗽、流鼻涕等有特效。但是4岁以下人群不可用,4-6岁遵医嘱。
附图说明:
图1为制备混悬液对乙酰氨基酚溶出曲线图,1表示本发明实施例1制备混悬液对乙酰氨基酚溶出曲线;2表示专利号为“2007800304895”说明书中实施例2制备混悬液对乙酰氨基酚溶出曲线。
图2为制备混悬液去氧肾上腺素溶出曲线图:1表示本发明实施例1制备混悬液盐酸去氧肾上腺素溶出曲线;2表示专利号为“2007800304895”说明书中实施例2制备混悬液盐酸去氧肾上腺素溶出曲线;
图3为制备混悬液马来酸氯苯那敏溶出曲线图,1表示本发明实施例1制备混悬液马来酸氯苯那敏溶出曲线;2表示专利号为“2007800304895”说明书中实施例2制备的混悬液马来酸氯苯那敏溶出曲线”。
图4为制备混悬液氢溴酸右美沙芬溶出曲线图;1表示制备本发明实施例1制备混悬液氢溴酸右美沙芬溶出曲线;2表示专利号为“2007800304895”说明书中实施例2制备的混悬液氢溴酸右美沙芬溶出曲线。
具体实施方式:
下例实施方式进一步描述和证明了本发明范围内的实施方案,所给出的这些实施例为了例举说明目的,不可看作是对本发明的限制。
本发明可由以下非限制性实施例方法进行制备:
实施例1(制备1000ml)
处方:
制备方法:
A、取处方量的马来酸氯苯那敏、盐酸去氧肾上腺素、对乙酰氨基酚和苯甲酸钠置洁净的容器中,加入55-65℃的纯化水适量,搅拌至熔融/或溶解状态,加入山梨醇,继续搅拌20-60min,静止,过滤,得物料1;
B、取处方量的微晶纤维素置均质机中,加入适量纯化水,用均质机(10000-20000r/s)均质搅拌20-50s,得物料2;
C、将上述物料1转移至物料2中,用均质机(10000-20000r/s)继续均质搅拌20-50s,得物料3;
D、取甘油置洁净的容器中,加入黄原胶,搅拌至熔融/或溶解,加入处方量的氢溴酸右美沙芬,搅拌均匀,55-65℃条件下搅拌30-60分钟,得物料4;
E、将物料3转移至物料4中,加入处方量的三氯蔗糖,亮蓝、诱惑红和葡萄香精,加入纯化水至配制量,搅拌100-150分钟,用无水枸橼酸调节PH值为4.7-5.0,继续搅拌至均质状态,过滤,即得本发明。
实施例2
处方:
A、取处方量的马来酸氯苯那敏、盐酸去氧肾上腺素、对乙酰氨基酚和山梨酸置洁净的容器中,加入55-65℃的纯化水适量,搅拌至熔融/或溶解状态,加入山梨醇,继续搅拌20-60min,静止,过滤,得物料1;
B、取处方量的微晶纤维素置均质机中,加入适量纯化水,用均质机(10000-20000r/s)均质搅拌20-50s,得物料2;
C、将上述物料1转移至物料2中,用均质机(10000-20000r/s)继续均质搅拌20-50s,得物料3;
D、取甘油置洁净的容器中,加入聚乙二醇,搅拌至熔融/或溶解,加入处方量的氢溴酸右美沙芬,搅拌均匀,55-65℃条件下搅拌30-60分钟,得物料4;
E、将物料3转移至物料4中,加入处方量的甜菊糖,柠檬黄,桔子香精,加入纯化水至配制量,搅拌100-150分钟,用无水枸橼酸调节PH值为4.5-5.0,继续搅拌至均质状态,过滤,即得本发明。
实施例3
A、取处方量的马来酸氯苯那敏、盐酸去氧肾上腺素、对乙酰氨基酚和苯甲酸置洁净的容器中,加入55-65℃的纯化水适量,搅拌至熔融/或溶解状态,加入丙二醇,继续搅拌20-60min,静止,过滤,得物料1;
B、取处方量的羟丙基甲基纤维素置均质机中,加入适量溶剂,用均质机(10000-20000r/s) 均质搅拌20-50s,得物料2;
C、将上述物料1转移至物料2中,用均质机(10000-20000r/s)继续均质搅拌20-50s,得物料3;
D、取甘油置洁净的容器中,加入黄原胶,搅拌至熔融/或溶解,加入处方量的氢溴酸右美沙芬,搅拌均匀,55-65℃条件下搅拌30-60分钟,得物料4;
E、将物料3转移至物料4中,加入处方量的三氯蔗糖,亮蓝,葡萄香精,加入纯化水至配制量,搅拌100-150分钟,用磷酸二氢钠调节PH值为4.5-5.0,继续搅拌至均质状态,过滤,即得本发明。
实施例4
用实施例1制备的混悬液与专利号为“2007800304895”,专利名称为“含有苯肾上腺素的药用混悬剂及其制备方法”(下述专利方法)说明书中实施例2制备的混悬液分别对盐酸去氧肾上腺素、马来酸氯苯那敏、对乙酰氨基酚和氢溴酸右美沙芬进行溶出度检测,比较不同时间药物的溶出度。
溶出度检测方法:采用HPLC法;
溶出曲线测定条件:
溶出介质:0.1mol/L盐酸,介质使用量:900ml;转篮转速:50转/min;取样量:10ml;取样间隔时间为5min;10min;20min;30min;45min;60min。
检测条件:色谱柱C18;检测波长:270nm;流动相A:缓冲盐(磷酸二氢钠30mol/l:辛烷磺酸钠2.5g/L):有机相(甲醇∶乙腈35∶65)90∶10;流动相B:缓冲盐(磷酸二氢钠30mmol/l:辛烷磺酸钠2.5g/L):有机相(甲醇∶乙腈35∶65)20∶80;PH值:3.0;柱温:30℃
1、对照品溶液的制备:
a、对乙酰氨基酚对照品溶液制备:
取对乙酰氨基酚对照品17.78mg至50ml的容量瓶中,加稀释剂(流动相A)适量,置超声波中超声5分钟,使其完全溶解,定容至刻线,再取1ml至100ml容量瓶中,用流动相A 定容至刻线,即可;
b、盐酸去氧肾上腺素对照品的制备:
取盐酸去氧肾上腺素对照品27.78mg置50ml的容量瓶中,加稀释剂(流动相A)适量,置超声波中超声5分钟,使其完全溶解,定容至刻线,再取0.5ml混合对照溶液至50ml容量瓶中,用流动相A定容至刻线,即可;
C、取马来酸氯苯那敏对照品11.11mg置50ml容量瓶中,制备方法同B;
D、取氢溴酸右美沙芬对照品55.56mg,置50ml容量瓶中,制备方法同B。
2、供试品溶液的制备:
分别量取0.1mol/L盐酸溶出介质六份,每份900ml,置6个溶出杯内,加温,待溶出介质温度恒定在37℃时,其中3个杯子加入实施例1各10ml,另3个杯子加入“专利方法”制备的样品各10ml,设定取样时间,每个时间段自动取样5ml,分6次取完,滤过,备用。
5、检测结果:见下表
不同时间检测溶出度一览表
结论:HPLC检测结果见说明书附图(图1、图2、图3、图4)。
从检测结果可以看出,本发明实施例1制备的混悬液比专利方法制备的混悬液溶出度高,特别是盐酸去氧肾上腺素、马来酸氯苯那敏和对乙酰氨基酚溶出度高达77%以上。
实施例5
以盐酸去氧肾上腺素含量为检测对象,用实施例1至实施例4制备的混悬剂进行稳定性考察:方法:
分别取实施例1至实施例4制备的混悬剂各30ml,置洁净的容器中,密封,放置恒温箱中,分别在25℃、相对湿度60%,30℃、相对湿度60%,35℃、相对湿度≤25%,40℃、相对湿度25%条件下储存,不同时间进行检查盐酸去氧肾上腺素含量。
结论:实施例1至实施例4经3个月和6个月稳定性试验考察,其降解率分别为0.07%、1.04%、1.34%和2.42%,其中实施例1降解率最低0.07%,总的降解率不超过3%。
需要指明的是,上述实施例虽然已经举例说明和描述本发明的具体方案,但是对本领域的技术人员来说显而易见的是,在不背离本发明实质和范围的情况下,可以做出其他组合物各物料量的改变和剂型的改变,因此,权利要求书意欲包括在本发明范围内所有组合物数量和剂型的改变。
Claims (13)
1.一种包含盐酸去氧肾上腺素组合物的制备工艺,1000ml含:药物活性成分:盐酸去氧肾上腺素0.5g、马来酸氯苯那敏0.2g、对乙酰氨基酚0.032g、氢溴酸右美沙芬1.00g;辅料:助溶剂1 50-150g、助溶剂2 600-800g、增稠剂0.8-2.0g、助悬剂1.00-10.00g、防腐剂0.8-1.5g、矫味剂1.00-5.00g、PH调节剂适量、色素10-40mg、香料1-3ml、溶剂适量组成,其特征在于制备方法如下:
1.1原辅料的处理:对乙酰氨基酚:粉碎,过80-120目筛;色素、香料:先分别用溶剂配制成一定浓溶液;
1.2取处方量的马来酸氯苯那敏、盐酸去氧肾上腺素、对乙酰氨基酚和防腐剂置洁净的容器中,加入55-65℃的溶剂适量,搅拌至熔融/或溶解状态,加入助溶剂2,继续搅拌20-60min,静止,过滤,得物料1;
1.3取处方量的助悬剂置均质机中,加入适量溶剂,用均质机(10000-20000r/s)均质搅拌20-50s,得物料2;
1.4将上述物料1转移至物料2中,用均质机(10000-20000r/s)继续均质搅拌20-50s,得物料3;
1.5取助溶剂1置洁净的容器中,加入增稠剂,搅拌至熔融/或溶解,加入处方量的氢溴酸右美沙芬,搅拌均匀,55-65℃条件下搅拌30-60分钟,得物料4;
1.6将物料3转移至物料4中,加入处方量的矫味剂,色素,香料,加入溶剂至配制量,搅拌100-150分钟,用PH调节剂调节PH值为4.5-5.0,继续搅拌至均质状态,过滤,即得本发明。
2.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述助溶剂1为甘油,助溶剂2为山梨醇。
3.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述增稠剂包括但不限于黄原胶、卡波姆、交联聚丙烯酸钠、泊洛沙姆、聚乙烯醇、海藻酸钠,进一步优选地黄原胶。
4.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述助悬剂包括但不限于微晶纤维素,聚乙烯吡咯烷酮水溶液或羟丙基甲基纤维素一种或几种,进一步优选微晶纤维素。
5.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述防腐剂包括但不限于苯甲酸、苯甲酸钠、山梨酸、山梨酸钠,进一步优选苯甲酸钠。
6.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述矫味剂包括但不限于蔗糖、甜菊素、三氯蔗糖,进一步优选三氯蔗糖。
7.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述PH调节剂包括但不限于磷酸氢钠、无水枸橼酸、磷酸二氢钾或磷酸二氢钠,进一步优选无水枸橼酸。
8.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述色素包括但不限于柠檬黄、橘黄、亮蓝、诱惑红,优选亮蓝与诱惑红混合物。
9.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述香料包括但不限于葡萄香精、苹果香精、桔子香精,优选葡萄香精。
10.如权利要求1所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于所述溶剂包括但不限于水、丙二醇、乙醇、聚乙二醇或他们的混合物。
11.如权利要求10所述水,其特征在于所述水为纯化水、去离子水或蒸馏水,本发明优选纯化水。
12.如权利要求1-10所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于优选的处方和制法如下:
12.1处方:1000ml中含:药物活性成分:盐酸去氧肾上腺素0.5g、马来酸氯苯那敏0.2g、对乙酰氨基酚0.032g、氢溴酸右美沙芬1.00g,辅料:甘油100.00g、山梨醇670.00g、黄原胶1.12g、微晶纤维素0.0075g、苯甲酸钠1.2g、三氯蔗糖2.4g、无水枸橼酸适量、纯化水适量;
12.2制法:
原辅料的处理:对乙酰氨基酚,粉碎,过80-120目筛;色素、香料分别用水配制成一定浓溶液;
12.2.1、取处方量的马来酸氯苯那敏、盐酸去氧肾上腺素、对乙酰氨基酚和苯甲酸钠置洁净的容器中,加入55-65℃的纯化水适量,搅拌至熔融/或溶解状态,加入山梨醇,继续搅拌20-60min,静止,过滤,得物料1;
12.2.2、取处方量的微晶纤维素置均质机中,加入适量纯化水,用均质机(10000-20000r/s)均质搅拌20-50s,得物料2;
12.2.3、将上述物料1转移至物料2中,用均质机(10000-20000r/s)继续均质搅拌20-50s,得物料3;
12.2.4、取甘油置洁净的容器中,加入黄原胶,搅拌至熔融/或溶解,加入处方量的氢溴酸右美沙芬,搅拌均匀,55-65℃条件下搅拌30-60分钟,得物料4;
12.2.5、将物料3转移至物料4中,加入处方量的三氯蔗糖、亮蓝、诱惑红,葡萄香精,加入纯化水至配制量,搅拌100-150分钟,用无水枸橼酸调节PH值为4.7-5.0,继续搅拌至均质状态,过滤,即得本发明。
13.如权利要求1-12所述一种包含盐酸去氧肾上腺素组合物的制备工艺,其特征在于其组合物对发热咽痛、鼻塞咳嗽、流鼻涕等有特效,4岁以下人群不可用,4-6岁遵医嘱。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010417513.8A CN111773203A (zh) | 2020-05-15 | 2020-05-15 | 一种包含盐酸去氧肾上腺素组合物的制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010417513.8A CN111773203A (zh) | 2020-05-15 | 2020-05-15 | 一种包含盐酸去氧肾上腺素组合物的制备工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111773203A true CN111773203A (zh) | 2020-10-16 |
Family
ID=72753877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010417513.8A Pending CN111773203A (zh) | 2020-05-15 | 2020-05-15 | 一种包含盐酸去氧肾上腺素组合物的制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111773203A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472678A (zh) * | 2020-11-12 | 2021-03-12 | 澳美制药厂有限公司 | 肾素那敏制剂及其制备方法 |
WO2023207815A1 (zh) * | 2022-04-27 | 2023-11-02 | 则正(上海)生物科技有限公司 | 含盐酸去氧肾上腺素片剂、制备方法及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080014274A1 (en) * | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
CN101505726A (zh) * | 2006-07-13 | 2009-08-12 | 麦克内尔-Ppc股份有限公司 | 含有苯肾上腺素的药用混悬剂及制备方法 |
CN109044968A (zh) * | 2018-10-18 | 2018-12-21 | 云南大唐汉方制药股份有限公司 | 氨酚右美肾素口服液及其制备方法 |
CN110279695A (zh) * | 2019-08-07 | 2019-09-27 | 北京博达绿洲医药科技研究有限公司 | 一种治疗流涕、鼻塞等感冒症状的药物组合物及其制备方法和用途 |
CN110302149A (zh) * | 2019-08-07 | 2019-10-08 | 北京博达绿洲医药科技研究有限公司 | 一种适合4-11岁儿童服用抗感冒药物及其制备方法 |
-
2020
- 2020-05-15 CN CN202010417513.8A patent/CN111773203A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101505726A (zh) * | 2006-07-13 | 2009-08-12 | 麦克内尔-Ppc股份有限公司 | 含有苯肾上腺素的药用混悬剂及制备方法 |
US20080014274A1 (en) * | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
CN109044968A (zh) * | 2018-10-18 | 2018-12-21 | 云南大唐汉方制药股份有限公司 | 氨酚右美肾素口服液及其制备方法 |
CN110279695A (zh) * | 2019-08-07 | 2019-09-27 | 北京博达绿洲医药科技研究有限公司 | 一种治疗流涕、鼻塞等感冒症状的药物组合物及其制备方法和用途 |
CN110302149A (zh) * | 2019-08-07 | 2019-10-08 | 北京博达绿洲医药科技研究有限公司 | 一种适合4-11岁儿童服用抗感冒药物及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472678A (zh) * | 2020-11-12 | 2021-03-12 | 澳美制药厂有限公司 | 肾素那敏制剂及其制备方法 |
WO2023207815A1 (zh) * | 2022-04-27 | 2023-11-02 | 则正(上海)生物科技有限公司 | 含盐酸去氧肾上腺素片剂、制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2567075C (en) | Pharmaceutical suspension composition | |
KR101695580B1 (ko) | 증가된 안정성의 신규한 액체 조성물 | |
EP3193887B1 (en) | Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions | |
EP2351554A1 (en) | Enhanced stability phenylephrine liquid compositions | |
NO303525B1 (no) | FremgangsmÕte for fremstilling av en farmas°ytisk sammensetning i gelform i en dispenseringspakning | |
TR201815803T4 (tr) | Bir aktif ajan, gliserin ve sorbitol içeren sıvı formülasyonlar. | |
EP3943066B1 (en) | Abuse deterrent formulations of amphetamine | |
CN111773203A (zh) | 一种包含盐酸去氧肾上腺素组合物的制备工艺 | |
EP2228054A1 (en) | Riluzole aqueous suspensions | |
CN112716903B (zh) | 一种氨氯地平干混悬剂及其制备方法 | |
CN109010341A (zh) | 一种含有氢溴酸右美沙芬的复方口服溶液及其制备方法 | |
JP6417480B2 (ja) | タダラフィル口腔崩解フィルム及びこの製造方法 | |
JP4851064B2 (ja) | 甲状腺ホルモン用医薬形態およびそれを得るための方法 | |
CN104127510B (zh) | 小儿热速清颗粒矫味组合物及其颗粒剂和制法 | |
CN108685876B (zh) | 一种含有利培酮的口服膜状药物组合物 | |
JP4866170B2 (ja) | 睡眠薬の放出制御医薬組成物及びその製造方法 | |
JPS61106509A (ja) | 鼻腔用医薬組成物 | |
WO2019004953A1 (en) | LEVOCLOPERASTIN FENDIZOATE SUSPENSION HAVING IMPROVED DISSOLUTION AND SUSPENSION CAPACITY | |
EP3095466B1 (en) | Pharmaceutical formulations with improved solubility and stability | |
JP2932086B2 (ja) | 新規なピコスルファートナトリウム液充填硬カプセル剤 | |
KR101458670B1 (ko) | 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법 | |
WO2013062497A1 (en) | Liquid pharmaceutical formulations | |
CN112716911B (zh) | 一种咖啡因微胶囊、其制备方法及复方氨酚烷制剂 | |
CN105663031A (zh) | 一种盐酸西替利嗪凝胶剂及其制备方法和应用 | |
CN115998739A (zh) | 一种治疗感冒症状的复方制剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |